Description: Hyloris Pharmaceuticals SA engages in the develop, manufacture, and deliver pharmaceutical products to address unmet medical needs in cardiovascular health, oncology, women's health, and other major therapeutic areas. The company offers cardiovascular products for atrial fibrillation, acute coronary syndrome, advanced heart failure, congestive heart failure, acute coronary syndrome, and coronary heart disease. It also provides other products, such as post operation pain, dental indications, severe and recurring vulvovaginal candidiasis, acute myeloid leukemia and small cell lung cancer, IC/PBS, attention deficit hyperactivity disorder, and viral infection. Hyloris Pharmaceuticals SA was incorporated in 2012 and is headquartered in Liège, Belgium.
Home Page: hyloris.com
Boulevard Gustave Kleyer 17
Liège,
4000
Belgium
Phone:
32 4 346 02 07
Officers
| Name | Title |
|---|---|
| Mr. Stijn Van Rompay | Co-Founder, CEO & Director |
| Mr. Thomas Jacobsen | Co-Founder, Chief Bus. Devel. Officer & Exec. Director |
| Mr. Jean-Luc Vandebroek | Chief Financial Officer |
| Dr. Dietmar Aichhorn Ph.D. | Chief Operating Officer |
| Ms. Marieke Vermeersch | VP Investor Relations & Corp. Communications |
| Mr. Koenraad Van Der Elst | Chief Legal Officer |
| Mr. Maurizio Passanisi | Chief Clinical Officer |
Exchange: BR
Country: BE
Currency: Euro (€)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 6.0635 |
| Price-to-Sales TTM: | 118.4742 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 21 |